Product Theater by Medimaps: Advancing Osteoporosis Management: Treatment Monitoring and Opportunistic Case-Finding with Trabecular Bone Score

Advancing Osteoporosis Management: Treatment Monitoring and Opportunistic Case-Finding with Trabecular Bone Score

Sunday, April 12, 2026, 1:00pm to 2:00pm Eastern Time (NY/USA)

Part 1: Trabecular Bone Score v4 and Treatment Responsiveness: Evidence from a Systematic Review and Meta-analysis
Summary:
This session will be presented by Dr Enisa Shevroja, MD, PhD, bone specialist and clinical researcher at the Bone Diseases Unit, CHUV Lausanne (Centre Hospitalier Universitaire Vaudois), Switzerland.
The presentation synthesizes evidence from randomized and prospective treatment studies to evaluate the responsiveness of TBS to osteoporosis therapies. The meta-analysis demonstrates consistent, treatment-specific changes in TBS that are biologically coherent with known effects on trabecular microarchitecture. These findings are examined in the context of methodological refinements introduced in TBS v4, including direct tissue thickness correction aimed at improving longitudinal precision.
Collectively, the accumulating clinical evidence supports a broader understanding of TBS within therapeutic assessment and suggests that combining TBS with BMD in longitudinal monitoring may enable a more tailored and biologically informed approach to osteoporosis management.
TBS, derived from the same DXA scan as BMD, has been reimbursed in the United States since 2022.

Part 2:  TBS Reveal: AI-enabled Bone Fragility Assessment from Routine X-rays
Summary:
This session will be presented by Prof Karen Hind, Honorary Professor at Lancaster Medical School, UK, and Vice President of Clinical Affairs, Research and Innovation at Medimaps Group.
Despite established diagnostic tools, it is estimated that up to 70% of individuals at risk of fracture remain unidentified or untreated for osteoporosis. TBS Reveal* has been developed to help close this gap by supporting opportunistic case-finding within everyday clinical practice.
The software enables physicians to assess bone fragility from X-rays that are already being performed for other clinical indications. No additional scans, radiation exposure, or disruption to workflow are required. By analysing the existing image, TBS Reveal provides a clear bone fragility category to support timely follow-up.
In this session, real-world performance data will be presented alongside examples of how this approach can fit naturally into routine radiology and orthopedic pathways. The discussion will focus on practical clinical value - identifying patients who might otherwise be missed, informing conversations about bone health, and supporting earlier, more proactive management before a fracture occurs.
*TBS Reveal is currently available as an RPO, and is pending FDA approval (SaMD).

Product Theaters are sponsored presentations and there is no credit available.